Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms

Table 1 Diagnostic performance of Oncuria assay in identifying high-grade/low-grade and high-stage/low-stage BC

Tumor Grade	Number of BC cases predicted by biomarker assay	AUC	Sensitivity (%)	Specificity (%)	NPV (%)	PPV (%)
Overall	42/45^a	0.95	0.93	0.93	0.99	0.65
Low-grade tumors^b	8/9	0.94	0.89	0.93	1.00	0.26
High-grade tumors^b	34/36	0.95	0.94	0.93	1.00	0.60
NMIBC	25/27	0.93	0.93	0.93	0.99	0.52
MIBC	15/16	0.97	0.94	0.93	1.00	0.39

NMIBC non-muscle-invasive bladder cancer, MIBC muscle-invasive bladder cancer, AUC Area under ROC curve, NPV negative predictive value, PPV positive predictive value
^a1 case was missing a single analyte and thus excluded
^bPer urogenital tumor classification scheme of the World Health Organization, 2022
N = 362 subjects presenting for bladder cancer evaluation. Instrumentation was Luminex 100/200 analyzer
Adopted from Hirasawa et al. [12] in accordance with unrestricted Creative Commons Attribution 4.0 International License BY-4.0

ISSN: 1479-5876